0001493152-26-010413
SEC filingAbeona Therapeutics Inc. (ABEO) reported total revenues of $5.8 million for FY 2025, a 100% increase from $0 in FY 2024, driven by $2.4 million in net product revenue from ZEVASKYN® following FDA approval in April 2025 and $3.4 million in license and other revenues from milestones. Despite this, total costs and expenses rose 48% to $95.3 million, primarily due to SG&A expenses surging 118% to $65.0 million from commercialization efforts and hiring. Operating loss widened 39% to -$89.4 million. However, net income swung to $71.2 million from a $63.7 million loss in 2024, boosted by a $152.4 million gain from selling a priority review voucher. Basic EPS was $1, compared to a prior-year loss. Cash resources stood at $191.4 million, with net cash used in operations at -$76.3 million, offset by $105.0 million from investing (PRV sale) and $26.0 million from financing. Balance sheet shows $219.6 million total assets, $60.4 million liabilities, and $159.2 million equity. Forward-looking, cash suffices for 12+ months, but ongoing commercialization of ZEVASKYN® and preclinical programs like ABO-503/504/505 require potential additional funding amid high R&D ($26.8M) and burn.
Abeona Therapeutics achieved FY2025 total revenues of $5.8M, up 100% from $0 in 2024, marking the first commercial year post-ZEVASKYN® FDA approval on April 28, 2025. Product revenue contributed $2.4M from initial ZEVASKYN® sales, including the first treatment in Q4 2025, while license revenues added $3.4M from Taysha milestone and AAV capsid option exercise. Costs escalated to $95.3M (+48% YoY), with SG&A at $65.0M (+118%) due to commercialization, hiring, and stock compensation. Operating loss expanded to -$89.4M (-39% YoY). Net income flipped to $71.2M from -$63.7M loss, propelled by $152.4M PRV sale gain (net of $2.6M costs). Basic EPS reached $1 vs prior loss. Cash resources totaled $191.4M, supporting operations amid -$76.3M operating cash use.
Revenues broke into product ($2.4M net, 42%) from ZEVASKYN® at qualified centers like Stanford, and license/other ($3.4M, 58%) from Rett syndrome milestone via Taysha and $0.4M AAV capsid license. No geographic split disclosed; U.S.-focused commercialization with 4 activated centers as of March 2026. Growth drivers: FDA approval enabling first sales; milestones from partnerships. No prior revenues, so 100% YoY surge. Royalties expense $1.9M tied to license milestone.
No explicit gross margin; revenues $5.8M minus cost of sales $1.5M and royalties $1.9M implies ~41% implied gross margin pre-other costs, vs N/A prior. Operating margin deeply negative at -1539% due to high fixed SG&A/R&D. Profitability hinged on one-time PRV gain; core ops loss-making with R&D $26.8M (-22% YoY from inventory capitalization post-approval) and SG&A ramp for launch.
Operating cash -$76.3M, adjusted for $71.2M net income, -$152.4M PRV gain (investing), +$10.8M stock comp, +$2.5M depreciation. Investing +$105.0M (PRV $152.4M net, short-term investments net -$39.3M, capex -$8.0M). Financing +$26.0M (ATM $17.3M, warrants $8.8M). Net cash increase $54.7M. Balance sheet: assets $219.6M (cash $78.4M, investments $113.0M, current $204.9M); liabilities $60.4M (debt $20.0M total); equity $159.2M. Liquidity $191.4M cash resources.
Management states cash sufficient through 12+ months; ATM remaining $51.5M capacity. Priorities: ZEVASKYN® commercialization (expand centers, insurer coverage incl. all Medicaid/J-code), preclinical AAV programs (ABO-503/504/505 paused to 2026). Risks: funding needs for commercialization/R&D, manufacturing delays, competition. No numerical guidance; expects SG&A/R&D increases.